Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report identifies a novel AR gene mutation in an adolescent with primary amenorrhea, suggesting that CAIS should be considered when evaluating patients with a female phenotype and breast development.

In this study, a low-glycemic index anti-inflammatory diet led to decreased testosterone levels, increased sex hormone-binding globulin, and improved well-being in overweight and obese women with hyperandrogenism, suggesting that diet and lifestyle changes can positively influence clinical symptoms.

This case report describes a 13-year-old with DSD raised as female, exhibiting hoarseness and clitoral enlargement, with hormonal assessments not indicating common related deficiencies.

This review discusses the influence of androgens on opioid-mediated effects and calls for further research into their role in sex differences and potential therapeutic options for chronic pain and substance use disorders.

This review identifies sebaceous gland disorders as key indicators of hormonal imbalances, detailing how various hormones affect sebaceous function, and emphasizes a multidisciplinary approach to improve diagnosis and management by integrating endocrine, metabolic, and dermatologic insights.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.

This review discusses the role of androgens in women's skin-related conditions like acne, hirsutism, and female pattern hair loss, noting the lack of dermatology guidelines for when to pursue endocrinologic evaluation.

This study found that shorter CAG-repeat lengths in the androgen receptor may be associated with the development of androgen-mediated skin disorders like androgenetic alopecia, acne, and hirsutism in both men and women.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This source highlights the essential role of androgens in women's health, noting their impact on various body systems and the critical need for more research on androgen therapies regarding side effects, patient selection, and laboratory standardization.

This review discusses hormone-modulating therapies for androgen-mediated cutaneous disorders in women but reports no new clinical results and highlights the need for more rigorous studies.

This review summarizes how common polymorphisms in androgen and estrogen receptor genes may influence aging-related symptoms and diseases in men, but it reports no new clinical results.

This study suggests that spironolactone may cause hormonally associated vestibulodynia and female sexual arousal disorder, with symptoms improving after discontinuation and use of a topical estrogen/testosterone gel.

This study confirms that finasteride inhibits the conversion of testosterone to dihydrotestosterone in human dermal fibroblasts, suggesting potential therapeutic use for androgen-related skin disorders.

This study found that antisense oligonucleotides successfully reduced androgen receptor expression in human keratinocytes and reconstituted human epidermis, suggesting potential for developing topical treatments.

This study found no baseline factors that predicted flibanserin efficacy for HSDD, though low testosterone or use of hormonal contraceptives were associated with reduced efficacy.

This review discusses guidelines for androgen use in women and concludes that more research is needed before recommending testosterone due to insufficient evidence on safety and efficacy.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

This review highlights the efficacy of transdermal testosterone therapy in improving sexual function in women with hypoactive sexual desire disorder, though approved formulations and long-term safety data are limited.

This review discusses the role of hormonal dysregulation and metabolic syndrome in hidradenitis suppurativa and reports no new clinical results.

This review presents substantial evidence supporting testosterone use for hypoactive sexual desire disorder in postmenopausal women, but notes safety concerns with off-label prescribing due to lack of approved formulations.

This review discusses the similarities in clinical, endocrine, and ultrasonographic features between PCOS and other disorders with excessive androgen secretion, emphasizing the importance of accurate diagnosis but reports no new clinical results.

This article discusses objective methods for assessing hair loss and notes that most types of hair loss can regrow without treatment, but effective treatments for pattern or senescent alopecia remain unavailable.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

This review discusses the hormonal impact on hair growth and the relationship between endocrine disorders and hair changes, reporting no new clinical results.

This comprehensive book on hair disorders covers various topics, including alopecia and hair replacement techniques, and provides extensive bibliographies but does not report new clinical results.

This review discusses the various causes of hirsutism other than PCOS, emphasizing the importance of distinguishing potentially life-threatening conditions like androgen-secreting tumors from more benign causes; it reports no new clinical findings.

This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.

This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.

This review summarizes the structural and chemical characteristics of current and novel antiandrogenic drugs but reports no new clinical findings.